Compounds > naltrexone

naltrexone and maraviroc

naltrexone has been researched along with maraviroc in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (83.33)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Arnatt, CK; Dever, SM; El-Hage, N; Hauser, KF; Jacob, JC; Selley, DE; Yuan, Y; Zhang, Y1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Arnatt, CK; El-Hage, N; Falls, BA; Hauser, KF; Knapp, PE; Masvekar, RR; Nicola, AV; Raborg, TJ; Selley, DE; Yuan, Y; Zhang, Y1
Barreto-de-Souza, V; Hauser, KF; Huang, B; Kang, G; Knapp, PE; Li, M; Nassehi, N; Selley, DE; Wang, H; Zhang, Y; Zheng, Y1
Arnatt, CK; Dever, SM; El-Hage, N; Hauser, KF; Podhaizer, EM; Zhang, Y1

Reviews

1 review(s) available for naltrexone and maraviroc

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

5 other study(ies) available for naltrexone and maraviroc

ArticleYear
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
A Bivalent Ligand Targeting the Putative Mu Opioid Receptor and Chemokine Receptor CCR5 Heterodimers: Binding Affinity versus Functional Activities.
    MedChemComm, 2013, May-01, Volume: 4, Issue:5

    Topics:

2013
Exploration of bivalent ligands targeting putative mu opioid receptor and chemokine receptor CCR5 dimerization.
    Bioorganic & medicinal chemistry, 2016, 11-15, Volume: 24, Issue:22

    Topics: Anti-HIV Agents; Cyclohexanes; Dimerization; Dose-Response Relationship, Drug; HIV Infections; HIV-1; Humans; Ligands; Maraviroc; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Naltrexone; Receptors, CCR5; Receptors, Opioid, mu; Structure-Activity Relationship; Triazoles

2016
Structure-Based Design and Development of Chemical Probes Targeting Putative MOR-CCR5 Heterodimers to Inhibit Opioid Exacerbated HIV-1 Infectivity.
    Journal of medicinal chemistry, 2021, 06-10, Volume: 64, Issue:11

    Topics: Analgesics, Opioid; Anti-HIV Agents; Binding Sites; Dimerization; Drug Design; HIV-1; Humans; Leukocytes, Mononuclear; Ligands; Maraviroc; Molecular Docking Simulation; Molecular Dynamics Simulation; Naltrexone; Phytohemagglutinins; Protein Binding; Receptors, CCR5; Receptors, Opioid, mu; Virus Internalization

2021
A novel bivalent HIV-1 entry inhibitor reveals fundamental differences in CCR5-μ-opioid receptor interactions between human astroglia and microglia.
    AIDS (London, England), 2013, Sep-10, Volume: 27, Issue:14

    Topics: Astrocytes; Cells, Cultured; Cyclohexanes; Genes, Reporter; HIV Fusion Inhibitors; HIV-1; Humans; Luciferases; Maraviroc; Microglia; Naltrexone; Receptors, CCR5; Receptors, Opioid; Triazoles; Virus Internalization

2013